Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Protagenic Therapeutics, Inc.\new | Chief Financial Officer | PTIX Common stock Options | 100K | $174K | $1.74 | Mar 25, 2024 | Direct |
Protagenic Therapeutics, Inc.\new | Chief Financial Officer | PTIX Common Stock | 45.8K | $37.1K | $0.81 | Oct 12, 2023 | Direct |
8i Acquisition 2 Corp. | Exit | Ordinary Shares, no par value | 3K | Nov 22, 2021 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
PTIX | Protagenic Therapeutics, Inc.\new | Mar 25, 2024 | 1 | $174K | 4 | Mar 29, 2024 | Chief Financial Officer |
PTIX | Protagenic Therapeutics, Inc.\new | Oct 12, 2023 | 1 | $6.48K | 4 | Oct 13, 2023 | Chief Financial Officer |
EUDA | EUDA Health Holdings Ltd | Nov 17, 2022 | 0 | $0 | 4 | Nov 25, 2022 | Exit |
PTIX | Protagenic Therapeutics, Inc.\new | May 17, 2022 | 2 | $22.1K | 4 | May 18, 2022 | Chief Financial Officer |
EUDA | 8i Acquisition 2 Corp. | Nov 22, 2021 | 0 | $0 | 3 | Nov 22, 2021 | Director |
PTIXW | Protagenic Therapeutics, Inc.\new | Jun 2, 2021 | 2 | $6.46K | 4 | Jun 3, 2021 | Chief Financial Officer |
PTIXW | Protagenic Therapeutics, Inc.\new | May 27, 2021 | 1 | $1.14K | 4 | Jun 1, 2021 | Chief Financial Officer |
PTIXW | Protagenic Therapeutics, Inc.\new | May 18, 2021 | 2 | $9.42K | 4 | May 20, 2021 | Chief Financial Officer |